Shares of Athenex, Inc. (ATNX) are currently gaining over 13% on Tuesday morning after the company announced that FDA accepted its NDA filing for oral paclitaxel and encequidar in metastatic breast cancer with priority review.
ATNX is currently trading at $13.00, up $1.51 or 13.14%, on the Nasdaq.
Athenex said FDA has granted a priority review for its New Drug Application for oral paclitaxel and encequidar for the treatment of metastatic breast cancer.
The FDA grants Priority Review to applications for potential drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.
The FDA has set a target action date of February 28, 2021.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.